University of Pennsylvania Study Shows Lipid Nanoparticles Successfully Engineer CAR T Cells In Vivo to Dissolve Pancreatic Tumor Barriers

University of Pennsylvania researchers use lipid nanoparticles to program T cells in vivo, successfully dissolving the protective shield around pancreatic tumors.

By: AXL Media

Published: Apr 1, 2026, 9:18 AM EDT

Source: Information for this report was sourced from University of Pennsylvania

Breaking the Desmoplastic Barrier in Pancreatic Cancer

Pancreatic ductal adenocarcinoma is notoriously resistant to traditional therapies due to a formidable structural defense known as the desmoplastic matrix. This dense barrier, composed of connective tissue and specialized fibroblasts, acts as a physical and immunological shield that prevents life saving treatments from reaching the tumor core. However, a research team led by the University of Pennsylvania School of Veterinary Medicine has demonstrated that lipid nanoparticles can be used to "melt away" this obstruction by directing the immune system to attack the very cells that maintain it.

In Vivo Engineering via Lipid Nanoparticles

Unlike conventional CAR T cell therapy, which requires a complex and expensive process of removing, modifying, and reinfusing a patient's T cells, the new approach uses lipid nanoparticles as delivery vehicles. These tiny fat based particles carry genetic instructions directly to T cells while they are still inside the patient's body. According to senior research investigator Khuloud Bajbouj, this method allows the patient's own biological systems to serve as the manufacturing site for cancer fighting cells, eliminating the need for high dose lymphodepletion and specialized laboratory facilities.

Targeting Fibroblast Activation Protein with Laser Focus

The research team specifically engineered the nanoparticles to equip T cells with the ability to identify and destroy fibroblast activation protein, or FAP. This protein is found in high concentrations on cancer associated fibroblasts, which are the primary architects of the tumor's protective matrix. By focusing the immune response on FAP positive cells, the researchers were able to dismantle the structural integrity of the tumor environment. This targeted approach has been described as a "laser focused" strategy that prioritizes the destruction of the tumor's support system rather than just the malignant cells themselves.